IP Library › Granted Patent US 9,808,627
Granted Patent B2
US 9,808,627 · App. 14/942,800 · Granted Nov 7, 2017

Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy

Inventors: Bradford Evan Gliner (Sammamish, WA); Allen Wyler (Seattle, WA); Brad Fowler (Woodinville, WA); W. Douglas Sheffield (Seatac, WA); Richard Kuntz (Lakebay, WA); Kent Leyde (Redmond, WA); Leif R. Sloan (Seattle, WA)
Assignee: ADVANCED NEUROMODULATION SYSTEMS, INC.
A61N1/36135A61N1/3606A61N1/36146A61N1/0531A61N1/0534A61N1/36064A61N1/36067A61N1/36082A61N1/36103A61N1/37252
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,808,627
App. No.
14/942,800
Granted
Nov 7, 2017
Kind
B2
Abstract

Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy are disclosed. In one embodiment, a system and/or method may apply electromagnetic stimulation to a patient's nervous system over a first time domain according to a first set of stimulation parameters, and over a second time domain according to a second set of stimulation parameters. The first and second time domains may be sequential, simultaneous, or nested. Stimulation parameters may vary in accordance with one or more types of duty cycle, amplitude, pulse repetition frequency, pulse width, spatiotemporal, and/or polarity variations. Stimulation may be applied at subthreshold, threshold, and/or suprathreshold levels in one or more periodic, aperiodic (e.g., chaotic), and/or pseudo-random manners. In some embodiments stimulation may comprise a burst pattern having an interburst frequency corresponding to an intrinsic brainwave frequency, and regular and/or varying intraburst stimulation parameters. Stimulation signals providing reduced power consumption with at least adequate symptomatic relief may be applied prior to moderate or significant power source depletion.

Claims (13)

1. A method of treating Parkinson's disease (PD) in a patient, the method comprising:

receiving one or more signals from a patient-controller input device that is indicative of self-administration of Levodopa or other dopamine agonist;

in response to the receiving, communicating one or more signals by the patient-controller input device to an implantable pulse generator to initiate a pre-defined stimulation protocol to accommodate for metabolization of the administered Levodopa or dopamine agonist, wherein the pre-defined stimulation protocol comprises:

(a) applying a first stimulation program, the first stimulation program including stimulation parameters selected to, provide an optimal stimulation therapy after a drug-onset time of the administered Levodopa or dopamine agonist;

(b) applying a second stimulation program, the second stimulation program including stimulation parameters selected to provide an optimal stimulation therapy for a drug half-life of the administered Levodopa or dopamine agonist; and

(C) applying a third stimulation program, the third stimulation program including stimulation parameters selected to provide an optimal stimulation therapy for drug level substantially below a level expected for the drug half-life of the administered Levodopa or dopamine agonist;

wherein the applying, the first, second, and third stimulation programs occurs automatically by the implantable pulse generator implanted in the patient in response to the implantable pulse generator receiving the one or more signals from the patient-controller input device, and wherein operation of the implantable pulse generator according to the second stimulation program provides reduced power consumption compared to operation of the implantable pulse generator according to the third stimulation program.

2. The method of claim 1 wherein the first stimulation program causes the implantable pulse generator to applying lower power stimulation to the patient compared to stimulation provided according to the second and third stimulation programs.

3. The method of claim 1 wherein the drug-onset time corresponds to an expected peak level of therapeutic benefit of the administered Levodopa or dopamine agonist.

4. The method of claim 1 wherein the first, second, and third stimulation programs employ different, burst rates for stimulation pulses applied during the first, second, and third stimulation programs.

5. The method of claim 1 wherein the stimulation pulses of the first, second, and third stimulation programs include timing-variations between successive bursts of pulses during the application of pulses of the first, second, and third stimulation programs.

6. The method of claim 1 wherein the implantable pulse generator switches between the first, second, and third stimulation programs according to measured times relative to the receipt of the one or more signals from a patient-controller input device indicative of self-administration of Levodopa or other dopamine agonist.

7. The method of claim 1 wherein the implantable pulse generator switches between the first, second, and third stimulation programs according to at least one sensor that generates a sensor signal indicative of patient activity.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: GLINER, BRADFORD EVAN; WYLER, ALLEN; FOWLER, BRAD; SHEFFIELD, W. DOUGLAS; KUNTZ, RICHARD; LEYDE, KENT; SLOAN, LEIF R.
To: NORTHSTAR NEUROSCIENCE, INC.
Reel/Frame 059399/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: NORTHSTAR NEUROSCIENCE, INC.
To: ADVANCED NEUROMODULATION SYSTEMS, INC.
Reel/Frame 059400/0248 →
Continuity (6)
Continuation 14101189 · Dec 9, 2013
Continuation 13179133 · Jul 8, 2011
Continuation 12327711 · Dec 3, 2008
Division 11182713 · Jul 15, 2005
Provisional Application 60588406 · Jul 15, 2004
Related Publication 20160067496A1 · Mar 10, 2016